Pharmaceuticals, Biotechnology and Life Sciences
Deadline to submit nominations is January 31, 2025WALTHAM, Mass., Oct. 21, 2024 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a…
Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader…
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio’s Oncology therapeutic area projections of…
CARSON CITY, Nev., Oct. 21, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company…
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage…
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) — Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular…
Saint-Herblain (France), October 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that…
Please find attached the first half 2024 financial report including the Responsibility Statement. ***** For further information, please contact: Alexander…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Lindis Biotech’s trifunctional Korjuny (catumaxomab), anti-CD3 x anti-EpCAM antibody (trAb) for the intraperitoneal treatment of malignant ascites (MA) in adults with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy.
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing…